Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Junli Lu,Yiming Luo,Dean Rao,Tiantian Wang,Zhen Lei,Xiaoping Chen,Bixiang Zhang,Yiwei Li,Bifeng Liu,Limin Xia,Wenjie Huang

DOI: https://doi.org/10.1186/s40164-024-00505-7

2024-04-14

Experimental Hematology and Oncology

Abstract:Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

oncology,hematology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the role of myeloid - derived suppressor cells (MDSCs) in cancer immune escape and their potential as targets for tumor immunotherapy. Specifically:

1. **Understanding the role of MDSCs in tumor development**: The paper explores how MDSCs participate in the formation of an immunosuppressive tumor microenvironment by exerting immunosuppressive effects, thereby promoting tumor immune escape. This involves the inhibitory mechanisms of MDSCs on the functions of multiple immune cells, especially T - cells.

2. **Specific mechanisms of MDSCs and tumor immune escape**: The paper discusses in detail the specific mechanisms by which MDSCs participate in immune escape in different tumor types, including metabolite consumption, generation of oxidative stress, blocking of T - cell homing, and expression of negative immune checkpoint molecules, etc.

3. **MDSCs as targets for tumor immunotherapy**: Given the important role of MDSCs in tumor immune escape, the paper explores the possibility of using MDSCs as immunotherapy targets, aiming to improve the response rate of cancer treatment and patient survival rate by eliminating or suppressing MDSCs.

4. **Interactions between MDSCs and other immune cells**: The paper also discusses the interactions between MDSCs and other immune cells (such as dendritic cells, natural killer cells, macrophages, and regulatory T - cells), and these interactions jointly promote tumor immune escape.

In summary, the main objective of this paper is to comprehensively understand the mechanism of action of MDSCs in tumor immune escape and explore their potential value as immunotherapy targets.